Sanofi Stock Slides as Vaccine Miss Overshadows Revenue Beat, Guidance Upgrade

Sanofi shares fell on Tuesday despite the French pharmaceutical giant reporting second-quarter revenue that beat analyst expectations and raising its full-year growth forecast, as investor focus turned to a shortfall in its vaccine unit and broader market caution.

Earnings Beat Fails to Lift Shares

The company reported Q2 2026 revenue of €11.6 billion, surpassing the consensus estimate of €11.2 billion, according to its latest earnings release. Buoyed by this performance, Sanofi lifted its full-year 2026 revenue growth target to approximately 10% at constant exchange rates, an upgrade from its previous goal of high single-digit growth.

Despite the positive headline figures, the stock traded down 1.6% to €78.62 in Paris, well below its 52-week high of €91.15, suggesting the market had already priced in a strong operational quarter.

Underlying Weakness and Pipeline Concerns

Investors appeared to zero in on specific weaknesses within the report and lingering questions about the company's drug pipeline. The results revealed that vaccine sales missed expectations, and sentiment remains weighed down by a recent development setback.

Key points of concern included:

Ad

• Vaccine Sales: The unit generated €1.15 billion, falling short of the €1.20 billion consensus amid what the company described as persistent demand softness.
• Pipeline Depth: A prior decision to abandon global regulatory filings for amlitelimab, a treatment for atopic dermatitis, continues to fuel concerns about Sanofi's future growth drivers.

These weaknesses overshadowed the continued blockbuster performance of Dupixent. The immunology drug saw sales of €5.15 billion, coming in 16% ahead of analyst forecasts and cementing its role as Sanofi's primary growth engine.

Broader Market Headwinds

The stock's decline also occurred within a challenging macroeconomic environment. Global equity markets have adopted a cautious tone after the U.S. Federal Reserve held interest rates steady on July 29 but signaled renewed inflation concerns, pushing bond yields higher.

This risk-averse backdrop appears to have prompted profit-taking in Sanofi shares, which had performed well leading up to the earnings event, rather than rewarding the company for its mixed results.